Skin aging Skin and Connective Tissue Diseases
Conditions
Interventions
Cohort 1 (aesthetic treatment cohort):
Prior to the aesthetic procedure, all participants will thoroughly cleanse the full facial treatment area. A 0.4–0.5 ml dose of 20% glycolic acid will be spread
the contralateral hemiface will receive placebo toner each morning and placebo toner plus lotion each evening. Participants attended four study visits: at baseline (D0), immediately after the aestheti
Sponsors
Shenzhen Hujia Technology Co., Ltd
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Asian female participants aged 18 to 60 years 2. Fitzpatrick skin phototypes III to IV 3. Presentation of mild to moderate facial skin concerns, including dullness, sallow complexion, erythema, rough texture, sagging, dry lines, fine lines, crow’s feet wrinkles and enlarged pores 4. Maintain a regular skincare routine and consistent use of sunscreen products 5. Have not received intense pulsed light (IPL) therapy or chemical peeling within 6 months prior to study commencement, and have not undergone any other aesthetic medical treatments within 1 year prior to study commencement 6. Have not applied topical retinoid preparations to the face within 6 months prior to study commencement, have no history of oral retinoid use, and have not used exfoliating products within 1 week prior to study commencement 7. Able to understand the trial procedures, take part voluntarily and provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding 2. Presentation of cutaneous disorders at the test site, such as psoriasis, allergic dermatitis and seborrhoeic dermatitis 3. Suffering from severe, unstable or progressive illnesses as judged by the investigator, including diabetes, hypertension, hypothyroidism or hyperthyroidism, which may alter the facial skin parameters under assessment 4. Expectation of receiving any treatments capable of interfering with trial outcomes throughout the study period, including systemic or topical anti-inflammatory agents, antihistamines, antibiotics and desensitisation therapy 5. Documented history of adverse cutaneous reactions to products belonging to the same category as the test cosmetic set. 6. Participation in, or current enrolment in, any other facial clinical testing within the preceding 1 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transepidermal water loss (TEWL) measured using Tewameter® TM HEX (Courage & Khazaka) at baseline (D0), immediately after aesthetic treatment before product application (D0´), and 7 days (D7), 28 days (D28) after product application;Skin hydration measured using Corneometer® CM825 (Courage & Khazaka) at baseline (D0), immediately after aesthetic treatment before product application (D0´), and 7 days (D7), 28 days (D28) after product application;Skin color measured using spectrophotometer® CM700d (Konica Minolta) at baseline (D0), immediately after aesthetic treatment before product application (D0´), and 7 days (D7), 28 days (D28) after product application;Skin elasticity R2 value, skin firmness F4 value measured using Cutometer® dual MPA580 (Courage & Khazaka) at baseline (D0), 7 days (D7), and 28 days (D28) after product application;Skin texture measured using Visioscan® VC20plus (COURAGE & KHAZAKA) at baseline (D0), 7 days (D7), and 28 days (D28) after product application;Wrinkles measured using Primos-CR® 300 (Canfield Scientific) at baseline (D0), 7 days (D7), and 28 days (D28) after product application | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin gloss measured using Glossymeter® GL200 (Courage & Khazaka) at baseline (D0), 7 days (D7), and 28 days (D28) after product application;Skin auto fluorescence (ASF) measured using Age Reader MU (Diagnoptic) at baseline (D0), 7 days (D7), and 28 days (D28) after product application | — |
Countries
China
Contacts
Public ContactYing Lyu
Outcome results
None listed